Aurinia Pharmaceuticals (AUPH) Cash & Current Investments (2016 - 2026)

Aurinia Pharmaceuticals has reported Cash & Current Investments for 11 years, with the latest figure at $378.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 21.06% year-over-year to $378.8 million; the trailing twelve-month figure through Mar 2026 stood at $378.8 million (up 21.06% YoY), and the FY2025 full-year result was $398.0 million, up 11.02% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $378.8 million, down from $398.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $418.8 million in Q1 2022, with the low at $312.9 million in Q1 2025.
• Historically, Cash & Current Investments has averaged $358.3 million across 5 years, with a median of $351.8 million in 2025.
• The largest YoY upside for Cash & Current Investments was 31.51% in 2022 against a maximum downside of 16.45% in 2022.
• Aurinia Pharmaceuticals' Cash & Current Investments stood at $389.4 million in 2022, then decreased by 9.99% to $350.5 million in 2023, then rose by 2.28% to $358.5 million in 2024, then climbed by 11.02% to $398.0 million in 2025, then retreated by 4.83% to $378.8 million in 2026.
• The last three Cash & Current Investments figures came in at $378.8 million (Q1 2026), $398.0 million (Q4 2025), and $351.8 million (Q3 2025), per Business Quant data.